SNDK has snapped back hard from its mid-week lows, and the most interesting development is not the price move itself but what is happening to the short base that was building during the selloff.
Short interest collapsed this week. From a sustained level above 10 million shares — where it had sat for most of June and early July — the reported position dropped to 6.6 million shares by July 10, a 37% single-week decline that cuts the short interest as a percentage of free float from roughly 7% to 4.5%. That is a meaningful reduction in a matter of days, and it coincides almost exactly with the stock's 10% weekly rally to $1,915.92. The borrow market reflects the same loosening: availability has expanded dramatically, now running at over 6,500% of short interest — an enormous pool of shares available to lend relative to what is actually borrowed. Cost to borrow, while technically doubling on a week-on-week basis to 0.32%, remains trivially low in absolute terms. The short score has also dropped sharply, falling from the high 30s to 32.96 on July 10. Taken together, the lending market is telling a story of retreating bearish conviction rather than building pressure.
Options positioning has also shifted. The put/call ratio has eased to 1.45, now running slightly below its 20-day average of 1.52 — a one-standard-deviation move in the less defensive direction. That is a notable change from the prior week, when the PCR was brushing its 52-week high near 1.65. The defensiveness that dominated options through late June and early July has started to unwind alongside the price recovery. Neither signal is at an extreme — this is a normalisation, not a capitulation.
The analyst backdrop remains overwhelmingly bullish, and the gap between Street targets and market price has begun to close, though it remains wide. BofA reiterated Buy with a $2,500 target as recently as July 1. Bernstein lifted to $3,000. The consensus mean sits at $2,035, implying roughly 6% upside from the current $1,916. After spending much of the past two weeks more than 20% below those targets — the central tension flagged in the two prior notes — the stock's recovery has eaten into that discount. Bulls point to structurally tight NAND supply and accelerating enterprise SSD demand driven by GenAI workloads. Bears retain a credible counter: the flash memory cycle is volatile, supplier concentration creates fragility, and hyperscaler qualification risk has not gone away. EPS momentum factor scores remain strong at the 89th and 97th percentiles over 30 and 90 days respectively, which supports the bull case on fundamentals. But the forward earnings yield multiple contracted over the past 30 days, suggesting the market is paying less for those earnings even as the estimates moved higher.
Insider activity adds a layer of caution to the recovery narrative. The CLO, CTO, and CFO have all been consistent sellers over the past 90 days. The net 90-day insider position amounts to $25 million in net sales across a small cluster of executives. None of these are catastrophic in size relative to the company, and the transactions span a period when the stock was trading at higher prices, but the pattern of sustained insider selling throughout the runup and subsequent drawdown is worth noting as the stock pushes back toward $2,000.
The next scheduled catalyst is earnings on August 5. The last two prints produced same-day moves of roughly 11% and 9% higher, with five-day post-earnings gains of 26% and 41% respectively — a consistently positive reaction pattern. The question heading into that date is whether the short base has now been cleared out enough, and whether options defensiveness has unwound sufficiently, that the market enters results without the hedged, cautious positioning that characterised the past three weeks.
See the live data behind this article on ORTEX.
Open SNDK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
